CVSGF Stock Chart & Stats
$16.60
-$0.69(-4.00%)
At close: 4:00 PM EDT
$16.60
-$0.69(-4.00%)
Day’s Range― - ―
52-Week Range$14.00 - $20.39
Previous CloseN/A
Volume165.00
Average Volume (3M)23.00
Market Cap
$1.20B
Enterprise Value$1.10B
Total Cash (Recent Filing)$12.30M
Total Debt (Recent Filing)$272.50M
Price to Earnings (P/E)58.2
Beta0.80
Next Earnings
Sep 24, 2026EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend Yield0.65%
Share Statistics
EPS (TTM)0.22
Shares Outstanding67,862,630
10 Day Avg. Volume0
30 Day Avg. Volume23
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.99
Price to Sales (P/S)1.33
P/FCF Ratio16.10
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit4.08
Enterprise Value/Ebitda8.90
Forecast
1Y Price Target
$22.73Price Target Upside36.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.01
Revenue Forecast (FY)$10.13M
Bulls Say, Bears Say
Bulls Say
Integrated Business ModelCVS's integrated model—clinics combined with in‑house diagnostics, crematoria and training—creates durable cross‑referral flows and diversified revenue streams. This structural integration increases client retention, utilization of lab services and revenue resilience across business cycles.
Strong Free Cash Flow GrowthA 90.10% rise in free cash flow indicates materially improved cash generation capacity. Sustained FCF supports reinvestment in clinics and labs, servicing or reducing debt, funding bolt‑on M&A and smoothing capital expenditures without relying on equity markets.
Improved LeverageDeleveraging to a 0.83 debt/equity ratio signals better balance sheet management. Lower leverage reduces interest cost sensitivity and raises financial flexibility, making it easier to fund capex, absorb shocks and pursue strategic acquisitions over the medium term.
Bears Say
Gross Margin CompressionA drop in gross margin from 42.93% to 38.58% points to structural cost or pricing pressure in core clinical and product sales. Persistent margin erosion reduces operating cash flow and narrows the buffer to absorb wage, supply or regulatory cost increases over time.
Low Net ProfitabilityA net margin near 2.9% limits retained earnings and reduces the company's ability to self‑fund expansion. Low bottom‑line profitability magnifies the impact of cost volatility and constrains returns to shareholders, tempering long‑term capital allocation options.
Weak Return On EquityLow ROE indicates the business is struggling to convert revenue and cash flow into attractive shareholder returns. Persistent weak ROE can reflect low incremental returns on acquisitions or inefficient capital deployment, limiting investor appeal and financing flexibility.
CVS Group plc News
CVSGF FAQ
What was CVS Group PLC’s price range in the past 12 months?
CVS Group PLC lowest stock price was $14.00 and its highest was $20.39 in the past 12 months.
What is CVS Group PLC’s market cap?
CVS Group PLC’s market cap is $1.20B.
When is CVS Group PLC’s upcoming earnings report date?
CVS Group PLC’s upcoming earnings report date is Sep 24, 2026 which is in 13 days.
How were CVS Group PLC’s earnings last quarter?
CVS Group PLC released its earnings results on Feb 26, 2026. The company reported $0.537 earnings per share for the quarter, missing the consensus estimate of $0.58 by -$0.043.
Is CVS Group PLC overvalued?
According to Wall Street analysts CVS Group PLC’s price is currently Undervalued.
Does CVS Group PLC pay dividends?
CVS Group PLC pays a Annually dividend of $0.112 which represents an annual dividend yield of 0.65%. See more information on CVS Group PLC dividends here
What is CVS Group PLC’s EPS estimate?
CVS Group PLC’s EPS estimate is 0.62.
How many shares outstanding does CVS Group PLC have?
CVS Group PLC has 67,862,630 shares outstanding.
What happened to CVS Group PLC’s price movement after its last earnings report?
CVS Group PLC reported an EPS of $0.537 in its last earnings report, missing expectations of $0.58. Following the earnings report the stock price went down -4.964%.
Which hedge fund is a major shareholder of CVS Group PLC?
Currently, no hedge funds are holding shares in CVSGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CVS Group plc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.73 (36.95% Upside)
$22.73 (36.95% Upside)
Insider Transactions
Bought Shares
Worth $67.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.90%
12-Months-Change
Fundamentals
Return on Equity
0.65%
Trailing 12-Months
Asset Growth
2.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CVS Group PLC
CVS Group plc, established in 1999 and based in Diss, United Kingdom, is a comprehensive animal care provider with diverse operations. The company's activities are broadly categorized into four segments: Veterinary Practices, Laboratories, Crematoria, and Online Retail. It manages a large network of animal veterinary clinics and complementary diagnostic laboratories. CVS Group also offers pet cremation services, including the disposal of clinical waste for veterinary practices, and provides pet burial grounds. Furthermore, the company operates Animed Direct, an e-commerce platform that functions as an online pharmacy and retail outlet, distributing both prescription and over-the-counter animal medications, premium pet nutrition, and various other pet care essentials. Additional services include the supply of veterinary instrumentation and referral services. Currently, CVS Group's portfolio comprises 506 veterinary practices, 3 laboratories, 7 crematoria, and a dedicated online pharmacy.
CVSGF Stock 12 Month Forecast
Average Price Target
$22.73
▲(36.95% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
13.55% Mutual Funds
― Other Institutional Investors
81.08% Public Companies and
Individual Investors








